Journal
MOLECULAR ONCOLOGY
Volume 15, Issue 2, Pages 347-349Publisher
WILEY
DOI: 10.1002/1878-0261.12880
Keywords
11q deletion; anti-GD2 therapy; immune checkpoint inhibition; microRNAs
Categories
Funding
- NIH [R35 CA220500]
- Giulio D'Angio Endowed Chair
Ask authors/readers for more resources
This study focused on the impact of hemizygous deletion of chromosome 11q on the response to immunotherapy in high-risk neuroblastoma, and explored potential transcriptional and post-transcriptional pathways that could be therapeutically targeted with biomarkers.
In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high-risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional and post-transcriptional pathways that may affect the response to immunotherapy and further be leveraged therapeutically in a biomarker-directed fashion.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available